Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases
Background: Long-term therapeutic adherence remains an essential challenge for better management of chronic diseases. It is estimated at 50% in developed countries. Objective: The study aimed to evaluate, under real conditions, the influence of satisfaction with Flexig use on adherence to subcutaneo...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Journal of Allergy and Clinical Immunology: Global |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S277282932300098X |
| _version_ | 1827353646542618624 |
|---|---|
| author | Taylor Pindi Sala, MD, PhD Daniel Matondo Masisa, MD, MPH Jean Charles Crave, MD, PhD Chafke Belmokhtar, PhD Guillaume LeNy, PhamD Hippolyte Situakibanza, MD, PhD Martin Duracinsky, MD, PhD Patrick Cherin, MD, PhD Olivier Chassany, MD, PhD |
| author_facet | Taylor Pindi Sala, MD, PhD Daniel Matondo Masisa, MD, MPH Jean Charles Crave, MD, PhD Chafke Belmokhtar, PhD Guillaume LeNy, PhamD Hippolyte Situakibanza, MD, PhD Martin Duracinsky, MD, PhD Patrick Cherin, MD, PhD Olivier Chassany, MD, PhD |
| author_sort | Taylor Pindi Sala, MD, PhD |
| collection | DOAJ |
| description | Background: Long-term therapeutic adherence remains an essential challenge for better management of chronic diseases. It is estimated at 50% in developed countries. Objective: The study aimed to evaluate, under real conditions, the influence of satisfaction with Flexig use on adherence to subcutaneous immunoglobulin home-treatment therapy in a sample of French patients with chronic dysimmune diseases. Methods: This is a 2-year prospective cohort involving 241 patients from several hospitals in France whose data were extracted from the Flexig 2.0 mHealth application. Satisfaction was assessed by System Usability Scale (SUS) and user experience by User Experience Questionnaire (UEQ). Adherence to Ig therapy was assessed by medication possession rate. We analyzed the relationship between Flexig user satisfaction and adherence to treatment, as well as determinants of adherence. Results: Most patients (82.7%) were being treated for an immunodeficiency, versus 17.3% for a chronic autoimmune and inflammatory disease. Almost all patients (97.9%) received subcutaneous immunoglobulin therapy. The patients’ ages (means ± SDs) were 36.5 ± 18.3 years, disease duration was about 6 years, and 58.5% were men. Flexig user satisfaction was 76.2 ± 8 (System Usability Scale), associated with good user experience reported on UEQ. Adherence rate was 99.7%. Time on app, disease duration, and Flexig user satisfaction were statistically predictive of adherence to IgG therapy. High adherence to Ig therapy was associated with good satisfaction with using Flexig (P < .0001). Conclusion: Adherence to Ig therapy in chronic dysimmune disease was strong and was associated with good satisfaction among Flexig users, suggesting that electronic support may be a valuable compliance aid. |
| first_indexed | 2024-03-08T03:29:30Z |
| format | Article |
| id | doaj.art-97cd8f91c8f14fe3b968412a360718d7 |
| institution | Directory Open Access Journal |
| issn | 2772-8293 |
| language | English |
| last_indexed | 2024-03-08T03:29:30Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Allergy and Clinical Immunology: Global |
| spelling | doaj.art-97cd8f91c8f14fe3b968412a360718d72024-02-11T05:12:54ZengElsevierJournal of Allergy and Clinical Immunology: Global2772-82932024-02-0131100173Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseasesTaylor Pindi Sala, MD, PhD0Daniel Matondo Masisa, MD, MPH1Jean Charles Crave, MD, PhD2Chafke Belmokhtar, PhD3Guillaume LeNy, PhamD4Hippolyte Situakibanza, MD, PhD5Martin Duracinsky, MD, PhD6Patrick Cherin, MD, PhD7Olivier Chassany, MD, PhD8ECEVE, UMR-S 1123, Université Paris Cité, Inserm, F-75004, Paris, France; Corresponding author: Taylor Pindi Sala, MD, PhD, ECEVE, UMR-S 1123, Université Paris Cité, Inserm, F-75004, Paris, France.Edistra Services, Bagnolet, FranceBioCryst France, Boulogne Billancourt, FranceOctapharma France, Boulogne Billancourt, FranceOctapharma France, Boulogne Billancourt, FranceDépartement de Médecine Interne, Département de Médecine Tropical, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the CongoECEVE, UMR-S 1123, Université Paris Cité, Inserm, F-75004, Paris, France; Patient-Reported Outcomes Research (PROQOL), Unité de Recherche Clinique en Economie de la Santé (URC-ECO), Hôpital Hôtel-Dieu, AP-HP, Paris, FranceDépartement de Médecine Interne et Immunologie Clinique, Groupement Hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, FranceECEVE, UMR-S 1123, Université Paris Cité, Inserm, F-75004, Paris, France; Patient-Reported Outcomes Research (PROQOL), Unité de Recherche Clinique en Economie de la Santé (URC-ECO), Hôpital Hôtel-Dieu, AP-HP, Paris, FranceBackground: Long-term therapeutic adherence remains an essential challenge for better management of chronic diseases. It is estimated at 50% in developed countries. Objective: The study aimed to evaluate, under real conditions, the influence of satisfaction with Flexig use on adherence to subcutaneous immunoglobulin home-treatment therapy in a sample of French patients with chronic dysimmune diseases. Methods: This is a 2-year prospective cohort involving 241 patients from several hospitals in France whose data were extracted from the Flexig 2.0 mHealth application. Satisfaction was assessed by System Usability Scale (SUS) and user experience by User Experience Questionnaire (UEQ). Adherence to Ig therapy was assessed by medication possession rate. We analyzed the relationship between Flexig user satisfaction and adherence to treatment, as well as determinants of adherence. Results: Most patients (82.7%) were being treated for an immunodeficiency, versus 17.3% for a chronic autoimmune and inflammatory disease. Almost all patients (97.9%) received subcutaneous immunoglobulin therapy. The patients’ ages (means ± SDs) were 36.5 ± 18.3 years, disease duration was about 6 years, and 58.5% were men. Flexig user satisfaction was 76.2 ± 8 (System Usability Scale), associated with good user experience reported on UEQ. Adherence rate was 99.7%. Time on app, disease duration, and Flexig user satisfaction were statistically predictive of adherence to IgG therapy. High adherence to Ig therapy was associated with good satisfaction with using Flexig (P < .0001). Conclusion: Adherence to Ig therapy in chronic dysimmune disease was strong and was associated with good satisfaction among Flexig users, suggesting that electronic support may be a valuable compliance aid.http://www.sciencedirect.com/science/article/pii/S277282932300098XTherapeutic adherenceFlexigmHealth appsubcutaneous immunoglobulinchronic dysimmunity diseaseshome monitoring |
| spellingShingle | Taylor Pindi Sala, MD, PhD Daniel Matondo Masisa, MD, MPH Jean Charles Crave, MD, PhD Chafke Belmokhtar, PhD Guillaume LeNy, PhamD Hippolyte Situakibanza, MD, PhD Martin Duracinsky, MD, PhD Patrick Cherin, MD, PhD Olivier Chassany, MD, PhD Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases Journal of Allergy and Clinical Immunology: Global Therapeutic adherence Flexig mHealth app subcutaneous immunoglobulin chronic dysimmunity diseases home monitoring |
| title | Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases |
| title_full | Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases |
| title_fullStr | Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases |
| title_full_unstemmed | Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases |
| title_short | Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases |
| title_sort | contribution of flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases |
| topic | Therapeutic adherence Flexig mHealth app subcutaneous immunoglobulin chronic dysimmunity diseases home monitoring |
| url | http://www.sciencedirect.com/science/article/pii/S277282932300098X |
| work_keys_str_mv | AT taylorpindisalamdphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT danielmatondomasisamdmph contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT jeancharlescravemdphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT chafkebelmokhtarphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT guillaumelenyphamd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT hippolytesituakibanzamdphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT martinduracinskymdphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT patrickcherinmdphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases AT olivierchassanymdphd contributionofflexigmobileapplicationtoassessadherenceofpatientstreatedwithimmunoglobulinsinchronicdiseases |